Table 2.
SPC therapies available for T2DM in the USA
| Brand name | Dosages, mg/mg | Administration | |
|---|---|---|---|
| Combinations with metformin | |||
| DPP-4 inhibitor + metformin | |||
| Alogliptin + metformin | Kazano® (Takeda Pharmaceuticals America, Inc.) | 12.5/500–12.5/1000 | Twice daily |
| Linagliptin + metformin | Jentadueto® (Boehringer Ingelheim Pharmaceuticals, Inc.) | 2.5/500–2.5/850–2.5/1000 | Twice daily |
| Linagliptin + metformin XR | Jentadueto® XR (Boehringer Ingelheim Pharmaceuticals, Inc.) | 2.5/1000 XR–5/1000 XR | Once daily |
| Saxagliptin + metformin XR | Kombiglyze® XR (AstraZeneca Pharmaceuticals, LP) | 2.5/1000 XR–5/500 XR–5/1000 XR | Once daily |
| Sitagliptin + metformin | Janumet® (Merck Sharp & Dohme Corp.) | 50/500–50/1000 | Twice daily |
| Sitagliptin + metformin XR | Janumet® XR (Merck Sharp & Dohme Corp.) | 50/500 XR–50/1000 XR–100/1000 XR | Once daily |
| SGLT2 inhibitor + metformin | |||
| Canagliflozin + metformin | Invokamet® (Janssen Pharmaceuticals, Inc.) | 50/500–50/1000–150/500–150/1000 | Twice daily |
| Canagliflozin + metformin XR | Invokamet® XR (Janssen Pharmaceuticals, Inc.) | 50/500 XR–50/1000 XR–150/500 XR–150/1000 XR | Once daily |
| Dapagliflozin + metformin XR | Xigduo® XR (AstraZeneca Pharmaceuticals, LP) | 5/500 XR–5/1000 XR–10/500 XR–10/1000 XR | Once daily |
| Empagliflozin + metformin | Synjardy® (Boehringer Ingelheim Pharmaceuticals, Inc.) | 5/500 –5/1000 – 12.5/500 – 12.5/1000 | Twice daily |
| TZD + metformin | |||
| Pioglitazone + metformin | Actoplus Met® (Takeda Pharmaceuticals America, Inc.) | 15/500–15/850 | Twice daily |
| Pioglitazone + metformin XR | Actoplus Met® XR (Takeda Pharmaceuticals America, Inc.) | 15/1000–30/1000 | Once daily |
| Rosiglitazone + metformin | Avandamet® (GlaxoSmithKline) | 2/500–4/500–2/10–4/1000 | Twice daily |
| SU + metformin | |||
| Glyburide + metformin | Generic | 2.5/500–5/500 | Twice daily |
| Combinations without metformin | |||
| DPP-4 inhibitor + TZD | |||
| Alogliptin + pioglitazone | Oseni® (Takeda Pharmaceuticals America, Inc.) | 12.5/15–12.5/30–12.5/45–25/15–25/30–25/45 | Once daily |
| SGLT2 inhibitor + DPP-4 inhibitor | |||
| Empagliflozin + linagliptin | Glyxambi® (Boehringer Ingelheim Pharmaceuticals, Inc.) | 10/5–25/5 | Once daily |
| TZD + SU | |||
|
Pioglitazone + glimepiride Rosiglitazone + glimepiride |
Duetact® (Takeda Pharmaceuticals America, Inc.) Generic |
30/2–30/4 4/1–4/2–4/4–8/2–8/4 |
Once daily Once daily |
Please consult full prescribing information for contraindications, warnings and precautions, and dosage and administration for use in specific populations (e.g., renal impairment)
DPP-4 dipeptidyl peptidase 4, SGLT2 sodium glucose cotransporter 2, SU sulfonylurea, T2DM type 2 diabetes mellitus, TZD thiazolidinedione, XR extended release